Drug Crisis: What is Arizona State Doing to Control the Epidemic?

Pre-Conditions for the Growth of Addiction

In the United States, drug overdose deaths have reached record levels in recent years, driven primarily by opioids such as fentanyl and other synthetic opioids. Opioids account for the majority of overdose deaths, but stimulants and polysubstance use (for example, opioids combined with benzodiazepines or alcohol) also contribute significantly. Legalization and expanded access to marijuana in many states have increased overall use, although the public health harms are far smaller than those associated with opioids and fentanyl. National surveillance data show that almost every state has been affected, with western states, including Arizona, seeing especially sharp increases in fentanyl-related deaths.

The current crisis is largely rooted in aggressive opioid prescribing that began in the late 1990s and 2000s, when prescription opioids were widely promoted for chronic pain and their addiction risk was underestimated. As prescribing tightened and many people with dependence lost legal access, some transitioned to heroin and, later, illicitly manufactured fentanyl, which is cheaper and vastly more potent. Fentanyl is now mixed into counterfeit pills and other street drugs, meaning many users do not know they are taking a potentially lethal dose. Broader social stressors—such as economic inequality, unemployment, mental health disorders, and social isolation—have further increased vulnerability to addiction and overdose. Inadequate access to evidence-based treatment, especially medications for opioid use disorder (MOUD), has allowed the crisis to deepen and persist.

Social and Economic Impacts

The opioid and broader drug crisis has placed extreme pressure on the U.S. healthcare system. Emergency departments and EMS services frequently respond to overdoses, often involving repeat visits by the same individuals, consuming substantial resources and staff time. Hospitals and clinics must manage complex co-occurring conditions, including infectious diseases (HIV, hepatitis C), mental health disorders, and chronic pain, which raises costs for both public and private insurers. At the same time, the need for medications like naloxone (Narcan) and buprenorphine, expanded behavioral health services, and harm-reduction programs has driven significant new public health spending. Families also bear heavy financial burdens in the form of treatment expenses, lost income, and long-term care needs for relatives who survive overdoses with serious complications.

Drug addiction also affects public safety and economic productivity. Law enforcement agencies devote substantial resources to disrupting drug trafficking and responding to overdose scenes, including the fentanyl supply that now dominates many illicit markets. Communities see increased property crime and other offenses linked to untreated addiction, while courts and correctional systems manage large dockets of drug-related cases. On the economic side, addiction contributes to reduced labor-force participation, absenteeism, workplace accidents, and premature death, all of which reduce overall productivity. The cumulative effect is a significant drag on local and national economies, along with deep and long-lasting social harm to families and neighborhoods.

Federal Countermeasures

The federal response has evolved rapidly in recent years, with a focus on fentanyl and other synthetic opioids. Below are five of the most recent and impactful federal actions aimed at combating the opioid and marijuana crisis.

National Strategy to Counter Illicit Fentanyl (Executive and Interagency Actions)

Federal agencies, including the Office of National Drug Control Policy (ONDCP), the Department of Homeland Security, the Department of Justice, and the Department of Health and Human Services, have adopted coordinated strategies specifically targeting illicitly manufactured fentanyl and its precursors. These strategies focus on disrupting supply chains from foreign chemical producers to Mexican cartels, improving border interdiction, and strengthening international cooperation with key source and transit countries. U.S. Customs and Border Protection and the Drug Enforcement Administration (DEA) have significantly expanded fentanyl seizures at and between ports of entry, measured in thousands of pounds per year. The strategy targets drug trafficking organizations, online distribution channels, and money-laundering networks that move fentanyl profits. By focusing on the highest-risk substances and organizations, these coordinated efforts aim to reduce the volume and potency of fentanyl reaching U.S. communities, thereby lowering overdose deaths.

DEA Aggregate Production Quotas and Controlled Substance Oversight

The DEA sets annual aggregate production quotas for Schedule I and II controlled substances, including prescription opioids, to limit the amount that can be manufactured in the United States. These quotas are adjusted based on medical need, abuse potential, and epidemiological data on overdoses and diversion. In recent years, the DEA has continued to tighten quotas for many high-risk opioids while maintaining access for legitimate medical use, especially for surgery, cancer, and palliative care. The quotas primarily target manufacturers and distributors, putting structural limits on the legal supply chain that previously contributed to widespread overprescribing. By restricting the volume of potent opioids in circulation, these measures are designed to reduce diversion into illicit markets and prevent new cases of prescription opioid addiction.

Expanded Access to Naloxone and Overdose Reversal Efforts

At the federal level, agencies such as the Substance Abuse and Mental Health Services Administration (SAMHSA) and the Centers for Disease Control and Prevention (CDC) have funded programs to expand community access to naloxone, the opioid overdose reversal medication. Federal grants support state and local distribution of naloxone to first responders, community organizations, families, and people who use drugs. The U.S. Food and Drug Administration (FDA) has also approved over-the-counter (OTC) formulations of naloxone, making it available without a prescription in many retail settings, which lowers barriers to life-saving intervention. These efforts target individuals at high risk of overdose, as well as their social networks, to ensure that naloxone is on hand when overdoses occur. By enabling rapid reversal of opioid overdoses, this federal push directly reduces mortality while people are connected to longer-term treatment and support.

Federal Investment in Medications for Opioid Use Disorder (MOUD) and Integrated Treatment

Federal agencies have increased funding and regulatory flexibility to expand access to evidence-based medications for opioid use disorder, such as buprenorphine, methadone, and extended-release naltrexone. Recent policy changes have eased prescribing requirements for buprenorphine and encouraged integration of addiction treatment into primary care, community health centers, and correctional settings. Grant programs administered through SAMHSA and other agencies fund state efforts to expand treatment capacity, particularly in underserved and rural areas. These initiatives target people with established opioid use disorder, including those leaving jail or prison, where overdose risk is especially high after release. By scaling up access to proven pharmacologic treatments, federal policy aims to reduce overdose risk, improve recovery outcomes, and stabilize individuals’ health and social functioning.

Federal Research and Surveillance on Substance Use and Marijuana Policy

The National Institute on Drug Abuse (NIDA) and other federal research bodies support extensive research on the causes, consequences, and treatment of substance use disorders, including marijuana and opioids. This research includes large national surveys, clinical trials, and studies of how state marijuana policies affect use patterns and health outcomes. Federal surveillance systems, coordinated through the CDC, track overdose deaths, emerging drug trends (such as new synthetic opioids), and geographic hotspots, which allows more targeted interventions. Policymakers use these data to refine prevention strategies, inform regulation of cannabinoids and other substances, and evaluate which approaches are most effective. While marijuana is less lethal than opioids, federal research helps identify risks such as impaired driving, youth use, and interactions with mental health disorders, guiding more nuanced responses than simple prohibition or unrestricted commercialization.

Arizona Case – The Numbers Speak for Themselves

Arizona has been hit especially hard by the fentanyl-driven phase of the opioid crisis. The Arizona Department of Health Services reports that more than five people die every day from opioid overdoses in the state, with prescription opioids and illegal opioids (including counterfeit pills containing fentanyl) as major contributors. In 2023, there were 2,624 drug overdose deaths in Arizona, corresponding to a rate of 35 deaths per 100,000 residents—one of the highest rates nationally. The Arizona Department of Education notes that in 2023 alone, more than 1,800 opioid-related deaths and over 4,000 overdoses were recorded across all age groups, with a growing share involving youth and counterfeit fentanyl pills. Local authorities, health agencies, and schools have launched targeted initiatives to expand naloxone access, increase prevention education, and coordinate treatment and law-enforcement efforts.

Mortality: According to recent data, more than 1,800 people in Arizona die each year from opioid-related causes, and total drug overdose deaths (from all substances) reached 2,624 in 2023. Fentanyl is now the deadliest drug in Arizona, with Maricopa County alone reporting more than three deaths per day on average from fentanyl overdoses. These figures highlight a worsening trend, especially among adolescents and young adults exposed to counterfeit pills and polysubstance combinations.

Key State Programs and Initiatives in Arizona

Arizona Opioid Public Health Emergency and ADHS Opioid Prevention Program

The Arizona Department of Health Services (ADHS) continues to operate a comprehensive opioid prevention program built on the statewide public health emergency declared in response to rising overdose deaths. The program requires rapid reporting of suspected overdoses within five business days, enabling near–real-time surveillance and targeted responses to emerging hotspots. ADHS works with healthcare providers, law enforcement, and community organizations to expand naloxone distribution, promote safer prescribing practices, and connect people with substance use disorder to treatment and recovery services.

STOP-IT and Narcan for Arizona K–12 Schools (Arizona Department of Education)

The Arizona Department of Education’s STOP-IT initiative responds to growing fentanyl overdoses among school-aged children by supplying K–12 schools with naloxone (Narcan) kits and related training. State law requires schools to have policies and procedures for emergency naloxone use, and the initiative provides guidance and support for complying with these requirements. In partnership with the Arizona Department of Health Services and the Arizona Health Care Cost Containment System, the program aims to ensure that schools are equipped to recognize overdoses quickly, administer naloxone, and prevent student deaths on campus.

Maricopa County “Focus on Fentanyl” Initiative

Maricopa County’s “Focus on Fentanyl” initiative brings together multiple county departments and elected offices to address fentanyl as Arizona’s deadliest drug. The program uses detailed data on fentanyl-related deaths to inform policy decisions, guide resource allocation, and support local prevention campaigns. It also promotes public awareness, provides information on free naloxone sources and treatment resources, and emphasizes prosecution of fentanyl dealers as a top public-safety priority.

Approaches in Neighboring Regions

Arizona shares borders with California, Nevada, Utah, New Mexico, and, internationally, Mexico. Three of the geographically closest U.S. states—California, Nevada, and New Mexico—have each adopted notable strategies to address the opioid and broader drug crisis. (Descriptions below synthesize current, widely reported state-level approaches based on federal and public health research; specifics are illustrative but consistent with current evidence-based practices.)

• California

  California has invested heavily in expanding access to medications for opioid use disorder (MOUD) through Medicaid (Medi-Cal), including integrating addiction treatment into primary care and mental health services. The state’s syringe services programs and naloxone distribution initiatives are designed to reach people who use drugs where they live, including homeless encampments and rural communities. California also funds extensive public education campaigns about fentanyl-contaminated pills and distributes test strips to help users detect fentanyl in street drugs. Together, these harm-reduction and treatment strategies aim to reduce overdose deaths, control infectious disease transmission, and encourage voluntary entry into treatment.

• Nevada

  Nevada has implemented statewide standing orders for naloxone, allowing pharmacists to dispense the medication without an individual prescription and making it widely available to families and community members. The state has expanded drug courts and diversion programs that connect people with substance use disorders to treatment instead of incarceration. Nevada’s health agencies promote data sharing between hospitals, emergency services, and public health authorities to identify overdose spikes and coordinate rapid responses. By combining legal reforms, treatment access, and real-time data, Nevada seeks to lower overdose mortality and reduce the criminalization of addiction.

• New Mexico

  New Mexico, long affected by high rates of opioid overdose, has focused on building a broad harm-reduction infrastructure, including syringe programs, naloxone distribution, and low-threshold MOUD services. The state supports mobile outreach teams that deliver services to rural and frontier areas where treatment access is limited. New Mexico also integrates behavioral health and substance use services within its Medicaid program, emphasizing continuity of care for people leaving jail or prison. These strategies aim to stabilize individuals at highest risk, reduce fatal overdoses, and address long-standing health inequities in rural and Native communities.

Is It Possible to Stop the Crisis? Looking to the Future

Approaches with Strong Potential Effectiveness

• Investment in Evidence-Based Treatment (Including MOUD)

  Expanding access to medications for opioid use disorder—such as buprenorphine, methadone, and extended-release naltrexone—has strong evidence for reducing overdose deaths and improving recovery outcomes. Integrating these treatments into primary care, mental health clinics, and correctional settings helps reach people who might not otherwise access specialty programs. Ensuring that treatment is covered by insurance, affordable, and geographically accessible is critical for sustained impact.

• Early Intervention and Youth Prevention

  Preventing addiction often means acting before substance use becomes entrenched, particularly in adolescence, when most addictions originate. School-based education programs, family support services, and mental health screening can identify at-risk youth and address underlying issues like trauma and depression. Efforts like Arizona’s STOP-IT initiative, which brings overdose education and naloxone into schools, are examples of early engagement with young people.

• Interagency and Cross-Sector Cooperation

  Coordinated efforts among public health agencies, healthcare systems, law enforcement, schools, and community organizations are more effective than isolated initiatives. Shared data systems and overdose surveillance enable rapid detection of new threats, such as changes in fentanyl supply or new synthetic drugs. Multi-sector coalitions can align resources toward common goals: reducing deaths, expanding treatment, and supporting long-term recovery.

• Public Education and Stigma Reduction Campaigns

  Educational campaigns that provide factual information about fentanyl, counterfeit pills, impaired driving, and signs of overdose help communities respond more effectively. Reducing stigma around addiction encourages people to seek help earlier and improves community support for harm-reduction and treatment services. Arizona’s public campaigns on fentanyl and “One Pill Can Kill” messaging illustrate how targeted education can influence behavior and awareness.

• Harm Reduction (Naloxone, Syringe Services, Fentanyl Test Strips)

  Harm-reduction services directly reduce fatal overdoses and infectious disease without requiring abstinence as a precondition for care. Widespread naloxone availability, clean syringe access, and tools like fentanyl test strips provide practical protections for people who continue to use drugs. These approaches create touchpoints through which individuals can be linked to treatment and other health and social services over time.

Approaches with Low Effectiveness or Proven Limitations

• Repressive Measures Alone (Punitive “War on Drugs” Tactics)

  Strategies focused primarily on arrest and incarceration of people who use drugs, without parallel investment in treatment and harm reduction, have not reduced addiction or overdose rates over the long term. High-intensity enforcement can disrupt supply temporarily but often leads to substitution with more potent, dangerous substances like fentanyl. Punitive approaches can also increase stigma and discourage people from seeking help or carrying naloxone.

• Unaccompanied Isolation and Abstinence-Only Approaches

  Forcing individuals into short-term abstinence, such as brief detox or incarceration without treatment, can lower tolerance and actually increase overdose risk upon release if they return to drug use. Without ongoing support, counseling, and MOUD where appropriate, relapse rates are high and health outcomes are poor. Evidence supports comprehensive, long-term treatment and recovery services rather than isolated, abstinence-only episodes.

• Lack of Aftercare and Recovery Supports

  Ending services after detox or a short residential stay, without follow-up care, housing support, and ongoing counseling, undermines the benefits of initial treatment. People leaving treatment, jail, or prison face high overdose risk if they are not connected to MOUD, primary care, and social supports. Effective systems provide step-down care, peer recovery support, and long-term follow-up to sustain recovery.

• Overly Simplistic Marijuana Policies (Either Total Prohibition or Unregulated Commercialization)

  Approaches that ignore evidence—for example, strict prohibition without public health support, or rapid commercialization without guardrails—can create new problems, including illicit markets, youth access, and impaired driving. More effective models combine regulation, age limits, product safety controls, and public education, especially where marijuana is legal for medical or adult use. Isolated punitive or laissez-faire measures tend to be less effective than balanced, data-informed regulatory frameworks.

Conclusions and Recommendations

The drug crisis in the United States—driven above all by fentanyl and other opioids—demands a sustained, data-driven public health response in every state. Arizona’s experience, with high overdose mortality and rapid growth in fentanyl-related deaths, underscores the urgency of combining prevention, harm reduction, treatment, and smart enforcement. Public health responsibility means recognizing addiction as a chronic disease, not a moral failure, and ensuring that communities have the tools to save lives and support recovery.

Each state will chart its own course, reflecting local needs, resources, and political choices. Yet successful strategies consistently rest on reliable data, open dialogue with affected communities, and long-term support for people living with addiction and their families. By investing in evidence-based care, fostering cooperation across sectors, and centering the dignity and safety of people who use drugs, states like Arizona can shift from crisis management toward a more hopeful and sustainable future.